anticoagulant

Biotech

BMS, J&J's secondary stroke med doesn't stick the landing

Bristol Myers Squibbs' anticoagulant milvexian failed its phase 2 trial but accrued enough encouraging data for the company to prep phase 3 plans.
Max Bayer Aug 28, 2022 3:36am

Racing Bayer, Merck gets FDA fast-track tag for anticoagulant

Aug 23, 2022 8:40am

Bayer-Ionis' anti-thrombotic med doesn't increase bleeding

Jul 28, 2022 10:51am

Amag merges with Perosphere, adding NOAC antidote

Dec 13, 2018 9:55am

Boston Sci to distribute Veniti’s venous stent

Sep 11, 2017 11:31am

Roche debuts iOS app for blood coagulation test device

Sep 26, 2016 11:18am